The Europe genome editing market accounted to US$ 1,052.9 Mn in 2017 and is expected to grow at a CAGR of 16.7% during the forecast period 2018 – 2025, to account to US$ 3,421.1 Mn by 2025.
The Asia Pacific genome editing market is expected to grow at highest rate during the forecast period owing to increasing investments by the governments of the respective countries in the region. In addition, the rise in the development and research for the genome editing along with the clinical trials are expected to fuel the market growth in Asia Pacific region.
To Know How COVID-19 Pandemic Will Impact Global Europe Genome Editing Market | Get a Sample Copy of Report, Click Here: https://www.theinsightpartners.com/sample/TIPRE00003908/
Rise in the Advancements for Genome Editing Technologies
The biotechnological field is characterized as a continuously developing the technologies for the betterment of the health for all the living organisms. Therefore, the technologies for the genome editing is undergoing various advancements, the most recent advancement for the genome editing is utilizing the nucleases which include the zinc finger nuclease (ZFN), transcription activators like effector nuclease (TALEN) and (clustered regulatory interspaced short palindromic repeats) CRISPR Cas9 system. The technologies has been successfully implemented in the several crops, including the Solanaceae plants, such as tomato, potato, tobacco, and petunia. CRISPR Case 9 among the three nucleases is the best for breeding, crop improvement, and the functional analysis of genes of interest. The technology is best due to its simplicity and high efficiency.
In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Transposagen Biopharmaceuticals, Inc.
Integrated DNA Technologies, Inc.
Thermo Fisher Scientific Inc.
Horizon Discovery Group plc
Sangamo Therapeutics, Inc.
New England Biolabs
Strategic acquisition and product launches were observed as the most adopted strategy in Europe genome editing industry. Few of the recent product launch and product approval are listed below:
2018: Thermo Fisher Scientific announced the acquisition of IntegenX. IntegenX has been developing rapid DNA testing technology for human identification for use in forensics and law enforcement. The company in 2015, has launched RapidHIT System, which is the first-generation STR-based human identification system that is also compatible with Thermo Fisher’s STR kits.
2017: Integrated DNA Technologies announced the product launch of variants of the first Cas9 enzyme. These are used for extensive reduction off-target effects in CRISPR genome editing and does not compromise on-target activity. The Alt-R S.p. HiFi Cas9 Nuclease 3NLS enzyme is a recombinant S. pyogenes Cas9 mutant improvises the specificity and also maintenance a high editing efficiency similar to wild-type Cas9.
2016: GenScript announced the launch of its new service CRISPR based Yeast Genome Editing Service. The service utilizes the λ Red-CRISPR/Cas9 technology.
NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.
The report is a combination of qualitative and quantitative analysis of the Europe Genome Editing industry. The global market majorly considers five major regions, namely, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America (SACM). The report also focuses on the exhaustive PEST analysis and extensive market dynamics during the forecast period.
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00003908/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.